| Literature DB >> 27619341 |
Julian E Mariampillai1, Per Anders Eskås1, Sondre Heimark1, Sverre E Kjeldsen2, Krzysztof Narkiewicz3, Giuseppe Mancia4.
Abstract
Although high blood pressure (BP) is the leading risk factors for cardiovascular (CV) disease, the optimal BP treatment target in order to reduce CV risk is unclear in the aftermath of the SPRINT study. The aim of this review is to assess large, randomized, and controlled trials on BP targets, as well as review selected observational analyses from other large randomized BP trials in order to evaluate the benefit of intense vs. standard BP control. None of the studies, except SPRINT, favored intense BP treatment. Some of the studies suggested favorable effects of lowering treatment target in patients with diabetes or high risk of stroke. In SPRINT, a new BP measurement method was introduced, and the results must be interpreted in light of this. The results of the observational analyses indicated the best preventive effect when achieving early and sustained BP control rather than low targets. In conclusion, today's guidelines' recommended treatment target of <140/90mmHg seems sufficient for most patients. Early and sustained BP control should be the main focus.Entities:
Keywords: Blood pressure; Blood pressure target; Cardiovascular disease; Clinical trial; Hypertension
Mesh:
Substances:
Year: 2016 PMID: 27619341 DOI: 10.1016/j.pcad.2016.09.002
Source DB: PubMed Journal: Prog Cardiovasc Dis ISSN: 0033-0620 Impact factor: 8.194